Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IntercureINCR +1.41%67 FCF Yield % is 5.42 as of Sep. 04, 2026. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Intercure ranks better than 75.27% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Intercure FCF Yield % Related Terms
Intercure FCF Yield % Historical Data
* Premium members only.
The historical data trend for Intercure's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercure FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intercure's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Intercure's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercure (INCR) has a FCF Yield % of 5.42 as of Sep. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Intercure and its competitors. According to the industry distribution chart, Intercure ranks #248 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is Intercure's FCF Yield % too high?
Intercure's current FCF Yield % is 5.42. The Drug Manufacturers industry median FCF Yield % is 0.75. Intercure's value of 5.42 is 622.7% above this industry median. Based on the distribution chart, Intercure ranks #248 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's FCF Yield % compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #248 out of 1003 companies for FCF Yield %. This places Intercure in the top 25% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.75. Intercure's value of 5.42 is 622.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.75, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intercure's current FCF Yield % of 5.42 is 622.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Intercure and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intercure's current FCF Yield % is 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.41 — trading 12.5% below its estimated fair value. The current FCF Yield % is 5.42 and 622.7% above the Drug Manufacturers industry median of 0.75. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Intercure (INCR), the current FCF Yield % is 5.42 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intercure (INCR) Overvalued in 2026?
Based on GuruFocus' analysis, Intercure stock appears to be undervalued.
The current stock price of $5.41 is trading 12.5% below its estimated GF Value™ of $6.18.
GuruFocus considers Intercure to be Modestly Undervalued.
Key valuation signals for INCR:
FCF Yield %: 5.42
GF Value™: $6.18 vs. price of $5.41 (12.5% below fair value)
Industry Position: 622.7% above the Drug Manufacturers median (#248 of 1003)
No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score
Get the complete analysis for INCR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCR has been successfully added to your 
